Recital 4, Directive (EU) 2002/98

In forcecited 3×

In respect of blood or blood components as a starting material for the manufacture of proprietary medicinal products, Directive 2001/83/EC refers to measures to be taken by Member States to prevent the transmission of infectious diseases, comprising the application of the monographs of the European Pharmacopoeia and the recommendations of the Council of Europe and the World Health Organisation (WHO) as regards in particular the selection and testing of blood and plasma donors. Furthermore, Member States should take measures to promote Community self-sufficiency in human blood or blood components and to encourage voluntary unpaid donations of blood and blood components.

  • Judgment of the Court (Fourth Chamber) of 29 April 2015. Geoffrey Léger v Ministre des Affaires sociales, de la Santé et des Droits des femmDecision

    Recitals 1, 2, 24 and 29 in the preamble to Directive 2002/98 state: The extent to which human blood is used therapeutically demands that the quality and safety of whole blood and blood components be ensured in order to prevent in …

    29 Apr 2015 · 62013CJ0528

  • Judgment of the Court (Third Chamber) of 8 June 2017. Medisanus d.o.o. v Splošna Bolnišnica Murska Sobota.Decision

    According to recitals 2, 4, 23 and 32 of Directive 2002/98, which governs various operations in relation to human blood: The availability of blood and blood components used for therapeutic purposes is dependent largely on Community …

    8 Jun 2017 · 62015CJ0296

  • Opinion of Advocate General Jääskinen delivered on 7 November 2013. Octapharma France SAS v Agence nationale de sécurité du médicament et deDecision

    Recital 4 of Directive 2002/98 recalls that Directive 2001/83 refers to measures to be taken by Member States to prevent the transmission of infectious diseases in respect of blood or blood components as a starting point for the …

    7 Nov 2013 · 62012CC0512